Storage and handling
Other information Use only if single-use container is intact. Use before expiration date marked on container. Store at 59°-86°F (15°-30°C) RETAIN THIS CARTON FOR FUTURE REFERENCE.
Other information Use only if single-use container is intact. Use before expiration date marked on container. Store at 59°-86°F (15°-30°C) RETAIN THIS CARTON FOR FUTURE REFERENCE.
Active ingredient Purpose
Carboxymethylcellulose sodium 0.5%...................................... Eye Lubricant
Uses
Warnings
For external use only
Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
To open, TWIST AND PULL TAB TO REMOVE. Instill 1 or 2 drops in the affected eye(s) as needed and discard container.
Other information
Inactive ingredients calcium chloride, magnesium chloride, potassium chloride, purified water, sodium chloride, and sodium lactate. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.
Distributed By:
Wal-Mart Stores Inc.
Bentonville, AR 72716
Made in Korea
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1188426 | carboxymethylcellulose sodium 0.5 % Ophthalmic Solution | PSN | 8 |
| 1188426 | carboxymethylcellulose sodium 5 MG/ML Ophthalmic Solution | SCD | 8 |
| 1188426 | carboxymethylcellulose sodium 0.5 % Ophthalmic Solution | SY | 8 |
| 1188426 | carboxymethylcellulose sodium 0.5 GM per 100 ML Ophthalmic Solution | SY | 8 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 49035-657-70 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-7089-d83d-e063-dadaa90ab31f | 7f2e8300-d789-40ab-bb23-a12dc2f42ba1 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49035-657-70 | Equate Restore Plus Lubricant Eye | 70 in 1 CARTON | SOLUTION/ DROPS | 70 | 8 | |
| 49035-657-70 | Equate Restore Plus Lubricant Eye | 0.4 mL in 1 VIAL, SINGLE-USE | SOLUTION/ DROPS | 0.4 | 8 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 49035-657-70 | EA - Each | 49035-657 | d4754041-d53b-404b-98b8-59ffbe4794dd | 1 | 2018-07-03 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CARBOXYMETHYLCELLULOSE SODIUM | ACTIVE INGREDIENT | K679OBS311 | 4 | |
| CARBOXYMETHYLCELLULOSE | ACTIVE MOIETY | 05JZI7B19X | 4 | |
| CALCIUM CHLORIDE | INACTIVE INGREDIENT | M4I0D6VV5M | 4 | |
| HYDROCHLORIC ACID | INACTIVE INGREDIENT | QTT17582CB | 4 | |
| MAGNESIUM CHLORIDE | INACTIVE INGREDIENT | 02F3473H9O | 4 | |
| POTASSIUM CHLORIDE | INACTIVE INGREDIENT | 660YQ98I10 | 4 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 4 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 4 | |
| SODIUM LACTATE | INACTIVE INGREDIENT | TU7HW0W0QT | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49035-657 | 49035-657-70 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CALCIUM CHLORIDE | M4I0D6VV5M | IACT |
| MAGNESIUM CHLORIDE | 02F3473H9O | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| SODIUM LACTATE | TU7HW0W0QT | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| CARBOXYMETHYLCELLULOSE SODIUM | K679OBS311 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / NASAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.18 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / NASAL | 20 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRATHECAL | ADJ PH | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | POWDER / RESPIRATORY (INHALATION) | 0.18 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBCUTANEOUS | 1486 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | LIQUID / NASAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAVENOUS | 720 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRA-ARTERIAL | 176 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION/ DROPS / OPHTHALMIC | 0.14 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / TOPICAL | 210 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / EPIDURAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CREAM / TOPICAL | 69 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ENDOTRACHEAL | 46.76 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAVENOUS | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / NASAL | NA | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRACAUDAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / EXTRACORPOREAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / TOPICAL | 0.86 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAPERITONEAL | 0.54 %w/v | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / IRRIGATION | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | GEL, METERED / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAOCULAR | ADJ PH | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | POWDER / NASAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, DENTIFRICE / DENTAL | 0.03 mg/mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / INTRATYMPANIC | 2 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / TOPICAL | 39 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | TABLET / ORAL | 10 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / PARENTERAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | JELLY / TOPICAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / SUBCUTANEOUS | 1037 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / IONTOPHORESIS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | DISC / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRALESIONAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / PERIDURAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, EMULSION / INTRAVENOUS | 0.62 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / TOPICAL | 0.2 %w/w | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | CAPSULE / RESPIRATORY (INHALATION) | 3 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAPLEURAL | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| SODIUM LACTATE | SODIUM LACTATE | TU7HW0W0QT | INJECTION / INTRAVENOUS | 54 mg | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / INTRATYMPANIC | 1 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / ORAL | 2 mg/5ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRACAUDAL | 210 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 136.55 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION, SOLUTION / INTRATHECAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2922 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SPRAY / NASAL | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.7 %w/w | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION / INTRAVENOUS | 1 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| HYDROCHLORIC ACID | HYDROCHLORIC ACID | QTT17582CB | INJECTION / RETROBULBAR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CREAM, AUGMENTED / TOPICAL | 6 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 6be3d3c3-8bb2-033a-e053-2a91aa0a3046 | 7f2e8300-d789-40ab-bb23-a12dc2f42ba1 | 2021-10-13 | Warnings | 6be3d3c3-8bb2-033a-e053-2a91aa0a3046 7f2e8300-d789-40ab-bb23-a12dc2f42ba1 |
Adverse event summaries are temporarily unavailable. Other product information remains available.